Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Currency impacts results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis

2Q Revenues: $14.3 billion (-4%)

2Q Earnings: $2.7 billion (flat)

YTD Revenues: $28.0 billion (-3%)  

YTD Earnings: $5.1 billion (-9%)

Comments: Pharmaceutical sales were $8.3 billion (-1%). Recently launched products helped offset the loss associated with the Diovan patent expiration. Lucentis, Gilenya, Afinitor, Tasigna and Galvus grew 8% to $4.1 billion. Currency had a negative impact of 5 percentage points. Alcon sales were up 1% to $2.6 billion in the quarter, driven by strong Surgical sales growth (+3%). Sandoz sales were down 13% to $2.1 billion, impacted by 7 percentage points of price erosion. Vaccines and Diagnostics sales were up 17% to $349 million, driven by Menveo. Consumer Health, which includes OTC and Animal Health, declined 24% to $904 million in the quarter, impacted by the suspension of production at the Lincoln, Nebraska manufacturing site.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters